Becton, Dickinson and Company $BDX Shares Sold by New York State Teachers Retirement System

New York State Teachers Retirement System lessened its stake in Becton, Dickinson and Company (NYSE:BDX) by 2.4% in the 2nd quarter, Holdings Channel.com reports. The firm owned 212,781 shares of the medical instruments supplier’s stock after selling 5,153 shares during the period. New York State Teachers Retirement System’s holdings in Becton, Dickinson and Company were worth $36,652,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in BDX. GQG Partners LLC acquired a new stake in shares of Becton, Dickinson and Company in the first quarter valued at approximately $689,833,000. Vanguard Group Inc. grew its position in Becton, Dickinson and Company by 4.7% in the first quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier’s stock worth $6,414,322,000 after acquiring an additional 1,259,750 shares during the period. Nuveen LLC purchased a new position in Becton, Dickinson and Company in the first quarter worth approximately $211,097,000. Kingstone Capital Partners Texas LLC purchased a new position in Becton, Dickinson and Company in the second quarter worth approximately $155,080,000. Finally, Massachusetts Financial Services Co. MA grew its position in Becton, Dickinson and Company by 10.8% in the first quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier’s stock worth $1,567,654,000 after acquiring an additional 667,957 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently weighed in on BDX. Piper Sandler reiterated a “neutral” rating and issued a $200.00 price objective (up from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Morgan Stanley increased their price objective on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $211.00 price objective on shares of Becton, Dickinson and Company in a research report on Thursday. Argus increased their price objective on Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Finally, Wall Street Zen upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Three investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $205.40.

Insider Transactions at Becton, Dickinson and Company

In related news, Director Claire Fraser sold 917 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the transaction, the director directly owned 22,226 shares in the company, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold 1,838 shares of company stock valued at $348,392 in the last ninety days. Company insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.9%

BDX opened at $185.08 on Friday. Becton, Dickinson and Company has a 52 week low of $163.33 and a 52 week high of $251.99. The business has a fifty day simple moving average of $190.69 and a 200-day simple moving average of $185.17. The firm has a market cap of $53.05 billion, a P/E ratio of 33.29, a P/E/G ratio of 1.46 and a beta of 0.25. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. The business had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%. On average, equities analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Investors of record on Monday, September 8th were issued a $1.04 dividend. The ex-dividend date was Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 74.82%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.